Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 08, 2026 06:00 ET | Source: AtaiBeckley Inc.

AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs

66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohortsDurable responses observed at Day 85:...
April 08, 2026 05:17 ET | Source: Research and Markets

Pharmacovigilance Market - Global Forecast 2026-2032: Increased Collaboration Across Sectors Present New Challenges and Opportunities for Patient Safety and Compliance

Dublin, April 08, 2026 (GLOBE NEWSWIRE) -- The "Pharmacovigilance Market - Global Forecast 2026-2032" report has been added to ResearchAndMarkets.com's offering. The Pharmacovigilance Market...
April 08, 2026 03:00 ET | Source: Aravax

Aravax Strengthens Board with Appointments of Carsten Hellmann and Andrew Oxtoby

MELBOURNE, Australia and OXFORD, United Kingdom, April 08, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for...
April 07, 2026 21:49 ET | Source: Leanzene

Leanzene Claims Evaluated: The Leading Keto BHB + ACV Weight Loss Gummy Brand on the Market

Leanzene BHB + ACV gummy claims evaluated: ingredient research, proprietary blend transparency, label vs. marketing analysis for consumers 2026
April 07, 2026 18:50 ET | Source: Robbins Geller Rudman & Dowd LLP

MEDP INVESTOR ALERT: Medpace Holdings Inc. Investors with Substantial Losses Have Opportunity to Lead the Medpace Class Action Lawsuit – RGRD Law

The case alleges Medpace oversold its projected book-to-bill ratio for fourth quarter 2025.
April 07, 2026 16:50 ET | Source: NovaBridge Biosciences

NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update

Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a...
April 07, 2026 16:15 ET | Source: Nanobiotix S.A.

Voting Rights and Shares Capital of the Company

PARIS, April 07, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com...
April 07, 2026 15:46 ET | Source: Pomerantz LLP

Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INO

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) and...
April 07, 2026 13:44 ET | Source: BCC Research LLC

Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications

Rapid expansion in clinical applications, rising demand for genomic diagnostics, and increased investment in CRISPR-based therapeutics are fueling demand.
April 07, 2026 12:13 ET | Source: Research and Markets

Purvalanol A (CDK Inhibitor) Market Report 2026: Expanding Molecular Biology and Cancer Research Fuelling Market Growth

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Purvalanol A (CDK Inhibitor) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Purvalanol A (CDK Inhibitor) market has...